Breaking
Top Investing Channel
Author

admin

Browsing

Hidden MACD SIGNAL? Key Trade Signals Explained!

In this exclusive StockCharts video, Joe breaks down reverse divergences (hidden divergence), key upside & downside signals, and how to use ADX and Moving Averages for better trades! Plus, he examines market trends and viewer symbol requests!

This video was originally published on February 26, 2025. Click this link to watch on Joe’s dedicated page.

Archived videos from Joe are available at this link. Send symbol requests to stocktalk@stockcharts.com; you can also submit a request in the comments section below the video on YouTube. Symbol Requests can be sent in throughout the week prior to the next show.

Argo Launches Digital Gold Investment Platform in the US, Aims to Disrupt Industry

Argo Digital US has launched its 24/7 gold investment platform in the US.

In an early February announcement, the Sprott family-backed company said the launch reflects its commitment to delivering safe and accessible gold investment opportunities, offering secure, digital access to physical gold.

“We believe Argo will appeal to the modern investor looking for a secure digital-first platform that meets their alternative investment needs,” said Argo Co-founder and President Michael Petch in a statement.

A market-driven launch

According to Argo, its analysis suggests that around 8.2 million retail investors could be open to investing in the yellow metal, representing a US$5.45 billion annual investment opportunity.

Data from the World Gold Council shows that annual gold investment reached a four year high of 1,180 metric tons in 2024, a 25 percent increase. In addition, Q4 demand value hit US$111 billion.

“This took 2024 over the line to reach the highest-ever annual value of US$382 billion,” the council notes.

Simplifying gold investment

Argo believes its gold investment platform brings a number of new elements to the table.

“(Our platform) is designed to provide retail investors with direct access to high-quality physical gold holdings. The platform was initially launched with a robust inventory of gold insured and securely stored with a trusted sovereign custodian, ensuring sufficient liquidity to meet investor demand,” the company said via email.

Argo is also committed to eliminating transaction fees to encourage investors to buy and sell gold.

“We have a highly competitive and transparent storage fee of just 0.12 percent, which is significantly lower than traditional gold investment options,” Petch said, adding that this eliminates hidden charges and high markups.

The platform exclusively holds Argo’s assets at present, but the company is open to expansion in the future.

“We are open to strategic partnerships and collaborations with reputable gold suppliers, institutions and investment platforms that align with our commitment to transparency and investor security,” Petch said.

Additional precious metals, in all their forms, will be added to the platform at a later date. There are also plans to integrate additional offerings, such as direct deposits and crypto-to-gold conversions in the future.

“Our founding team’s long-standing success in the precious metals markets and asset management industry gives us deep confidence in Argo Digital Gold’s expansion into the US,” Argo Co-Founder and Chair Peter Grosskopf added.

“As we introduce a modernized platform to the process of buying one of the world’s oldest alternative assets, (we are) seeking to disrupt the US$3.2 trillion gold investment industry by enabling easy and direct ownership of precious metals.’

On payments and privacy

Argo supports automated clearinghouse and wire transfers, with additional payment options to be added later.

When asked about security, Argo said it has implemented stringent data protection measures to safeguard user data, including industry-standard encryption, secure authentication protocols and compliance with regulatory frameworks.

“Our platform operates with a zero-compromise approach to privacy, ensuring that personal and financial details are protected against unauthorized access,” Petch said. He also noted that all gold holdings are fully insured and stored with trusted institutional partners for an added layer of security and confidence for Argo’s investors.

Gold growth

According to Argo, gold has demonstrated an impressive average annual growth rate of 8 percent in US dollars since 1971, supported by its inverse correlation to the stock market in periods of risk.

The precious metal has reached multiple new highs in 2025 already, breaking US$2,950 per ounce on February 20 on the back of ever-increasing global turmoil, including tariff talks and tensions between Russia and Ukraine.

Even so, many market watchers believe gold’s run isn’t over.

“How much higher? It is hard to say, but a real all-time-high of just under US$3,500 is less than 35 percent higher than where we are today. That seems doable,” Lobo Tiggre, CEO of IndependentSpeculator.com, said at the end of 2024.

Securities Disclosure: I, Gabrielle de la Cruz, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Could Bitcoin Reach $200000? Market & Expert Insights

Bitcoin attracts bold predictions. Recent forecasts show that this top cryptocurrency may soon hit Bitcoin Reach $200000. Many trusted sources, including Yahoo Finance, CoinDesk, Bloomberg, and CNBC, have reported this forecast. This public news reflects rising optimism among market experts amid changing economic conditions.

Market Sentiment and Economic Drivers

Many analysts believe that economic uncertainty and rising prices create a strong chance for Bitcoin to serve as a safe asset. Investors now see Bitcoin as a reliable store of value. They shift funds to cryptocurrencies when they lose trust in traditional assets. In addition, new regulations in key markets push both large and small investors to spread their money across various assets.

Technical Analysis and Price Trends

Technical data supports a potential price surge. Long-term charts show an upward trend, while short-term drops offer good buying points. Trading volumes and network activity grow each day. Experts point to a limited supply and high demand as key reasons that Bitcoin Reach $200000 upto.

Investor Implications and Risk Management

Investors must stay alert in this volatile market. They should manage risk by diversifying their portfolios. Many experts advise reviewing holdings and allocating funds wisely. They also recommend keeping up with the latest market news and technical signals to guide decisions.

Conclusion

This forecast that Bitcoin may reach $200,000 comes from strong market sentiment, positive technical trends, and a unique economic climate. However, investors face a volatile market that demands caution. Experts urge both individual and institutional investors to monitor these trends closely and prepare for various market moves.

While reaching $200,000 is not guaranteed, this forecast offers valuable insight into the ever-changing crypto market. It shows that the market can shift quickly and that informed decisions are key. Investors should act wisely and stay updated on news and trends. By doing so, they can protect their investments and uncover new opportunities in the fast-paced world of cryptocurrencies.

The post Could Bitcoin Reach $200000? Market & Expert Insights appeared first on FinanceBrokerage.

Bucking trend, McDonald’s vows no egg surcharges as it preps $1 Egg McMuffin Day

McDonald’s is leaning into its reputation as a breakfast value offering, vowing to reject a surcharge on meals with eggs while announcing a special one-day discount on Egg McMuffins.

The fast-food giant said in a release that to mark the 50th anniversary of its breakfast-menu cornerstone, customers on Sunday would be able to purchase an Egg McMuffin sandwich, as well as a Sausage McMuffin With Egg sandwich, through the McDonald’s app for just $1.

“At McDonald’s, breakfast isn’t just a meal; it’s a cherished tradition and cornerstone of our brand,” McDonald’s USA President Joe Erlinger said Tuesday. “Every morning when we open our doors, we are a breakfast restaurant.”

Coinciding with the release, a McDonald’s executive emphasized in a LinkedIn post that the chain had no intention to charge customers extra for meals featuring eggs amid a nationwide shortage that has sent prices soaring and prompted at least two other national chains to do so.

‘Unlike others making news recently, you definitely WON’T see McDonald’s USA issuing surcharges on eggs, which are 100% cage-free and sourced in the U.S.,’ wrote Michael Gonda, McDonald’s chief impact officer for North America.

The announcements come as McDonald’s tries to leave a recent slump behind: Earlier this month, it reported its worst quarterly sales drop since the pandemic — but forecast improving results for 2025.

Year to date, its shares are up some 6%, outperforming broader market indexes.

This post appeared first on NBC NEWS

Nvidia to report earnings amid infrastructure spending, DeepSeek concerns

Nvidia is scheduled to report fourth-quarter financial results on Wednesday after the bell.

It’s expected to put the finishing touches on one of the most remarkable years from a large company ever. Analysts polled by FactSet expect $38 billion in sales for the quarter ended in January, which would be a 72% increase on an annual basis.

The January quarter will cap off the second fiscal year where Nvidia’s sales more than doubled. It’s a breathtaking streak driven by the fact that Nvidia’s data center graphics processing units, or GPUs, are essential hardware for building and deploying artificial intelligence services like OpenAI’s ChatGPT. In the past two years, Nvidia stock has risen 478%, making it the most valuable U.S. company at times with a market cap over $3 trillion.

But Nvidia’s stock has slowed in recent months as investors question where the chip company can go from here. 

It’s trading at the same price as it did last October, and investors are wary of any signs that Nvidia’s most important customers might be tightening their belts after years of big capital expenditures. This is particularly concerning in the wake of recent breakthroughs in AI out of China. 

Much of Nvidia’s sales go to a handful of companies building massive server farms, usually to rent out to other companies. These cloud companies are typically called “hyperscalers.” Last February, Nvidia said a single customer accounted for 19% of its total revenue in fiscal 2024.

Morgan Stanley analysts estimated this month that Microsoft will account for nearly 35% of spending in 2025 on Blackwell, Nvidia’s latest AI chip. Google is at 32.2%, Oracle at 7.4% and Amazon at 6.2%.

This is why any sign that Microsoft or its rivals might pull back spending plans can shake Nvidia stock.

Last week, TD Cowen analysts said that they’d learned that Microsoft had canceled leases with private data center operators, slowed its process of negotiating to enter into new leases and adjusted plans to spend on international data centers in favor of U.S. facilities.

The report raised fears about the sustainability of AI infrastructure growth. That could mean less demand for Nvidia’s chips. TD Cowen’s Michael Elias said his team’s finding points to “a potential oversupply position” for Microsoft. Shares of Nvidia fell 4% on Friday.

Microsoft pushed back Monday, saying it still planned to spend $80 billion on infrastructure in 2025.

“While we may strategically pace or adjust our infrastructure in some areas, we will continue to grow strongly in all regions. This allows us to invest and allocate resources to growth areas for our future,” a spokesperson told CNBC.

Over the last month, most of Nvidia’s key customers touted large investments. Alphabet is targeting $75 billion in capital expenditures this year, Meta will spend as much as $65 billion and Amazon is aiming to spend $100 billion.

Analysts say about half of AI infrastructure capital expenditures ends up with Nvidia. Many hyperscalers dabble in AMD’s GPUs and are developing their own AI chips to lessen their dependence on Nvidia, but the company holds the majority of the market for cutting-edge AI chips.

So far, these chips have been used primarily to train new age AI models, a process that can cost hundreds of millions dollars. After the AI is developed by companies like OpenAI, Google and Anthropic, warehouses full of Nvidia GPUs are required to serve those models to customers. That’s why Nvidia projects its revenue to continue growing.

Another challenge for Nvidia is last month’s emergence of Chinese startup DeepSeek, which released an efficient and “distilled” AI model. It had high enough performance that suggested billions of dollars of Nvidia GPUs aren’t needed to train and use cutting-edge AI. That temporarily sunk Nvidia’s stock, causing the company to lose almost $600 billion in market cap. 

Nvidia CEO Jensen Huang will have an opportunity on Wednesday to explain why AI will continue to need even more GPU capacity even after last year’s massive build-out.

Recently, Huang has spoken about the “scaling law,” an observation from OpenAI in 2020 that AI models get better the more data and compute are used when creating them.

Huang said that DeepSeek’s R1 model points to a new wrinkle in the scaling law that Nvidia calls “Test Time Scaling.” Huang has contended that the next major path to AI improvement is by applying more GPUs to the process of deploying AI, or inference. That allows chatbots to “reason,” or generate a lot of data in the process of thinking through a problem.

AI models are trained only a few times to create and fine-tune them. But AI models can be called millions of times per month, so using more compute at inference will require more Nvidia chips deployed to customers.

“The market responded to R1 as in, ‘oh my gosh, AI is finished,’ that AI doesn’t need to do any more computing anymore,” Huang said in a pretaped interview last week. “It’s exactly the opposite.”

This post appeared first on NBC NEWS

Decode the Stock Market’s Health With This Key Indicator

The US Consumer Confidence Index® came in much lower than expectations, and the Expectations Index fell to 72.9. A fall below 80 signals a recession ahead, enough to elevate the fear of economic weakness. As a result, the stock market sold off. But after 11:30 AM ET, the buyers came in, and the market rebounded from its lows. However, the rebound wasn’t enough to make much of a dent, except for the Dow which closed in the green. 

If you regularly monitor breadth indicators, you may have noticed that the New Highs – New Lows Index ($NYHL) was up over 150%. This caught my attention. The broader equity indexes were falling significantly, yet the new highs were way higher than the new lows. That was unusual, but since the stock market is known for pulling surprises when you least expect it to, it’s helpful to look under the hood to determine if the stock market is strong or weak. 

The Market’s Heart Beat

Looking through the rest of my charts in my Market Analysis ChartList — a part of my daily routine — one that I found interesting is the SPDR S&P 500 ETF (SPY) with the Percent Above Moving Average oscillators in the lower panels (see chart below).

FIGURE 1. DAILY CHART OF SPY. The percentage of S&P 500 stocks trading above their 50-, 100-, and 200-day simple moving averages are above 50 but watch these oscillators closely as they indicate the health of the overall market. Chart source: StockCharts.com. For educational purposes.

It’s interesting to note that the percentage of S&P 500 stocks trading above their 50-, 100-, and 200-day simple moving averages (SMAs) started to decline at the end of September 2024. The SPY was still trending higher and it wasn’t till December when it started to pull back.

The September pullback coincided with a relatively low percentage of stocks trading below their moving averages and declined further during the January 2025 pullback. But the oscillators recovered from these levels and as of now, even though SPY bounced off its 100-day moving average, they are not close to the previous lows. The good thing is they are all above their 50 threshold level. You can’t say the same for the Nasdaq stocks.

The chart below replaces SPY with Invesco QQQ Trust (QQQ) and analyzes the percentage of Nasdaq stocks trading above the 50-, 100-, and 200-day SMAs. They are trading at levels seen in August 2024, which is when QQQ went through a -15.56% pullback.

FIGURE 2. DAILY CHART OF QQQ. Although the QQQ is holding on to the support of its 100-day SMA, the percent of stocks trading below their moving averages are below 50, which is a bearish indication. Chart source: StockCharts.com. For educational purposes.

The Technology sector witnessed a four-day losing streak and was the worst-performing sector in the last week. Tech stocks are facing many headwinds — tariffs, AI unwinding, and chip availability, to name a few. Investors are rotating out of Tech stocks and moving into the offensive sectors — Consumer Staples, Real Estate, and Health Care. 

The Bottom Line

The broader stock market is at an interesting juncture and could go either way. SPY and QQQ are holding on to the support of their 100-day SMA but two important news events could shake things either way — NVIDIA earnings and Personal Consumption Expenditures Price Index (PCE). The rest of the week could be a bumpy ride.

If you haven’t done so, apply the percentage of stocks trading above significant moving averages oscillator. Percentage Above Moving Average indicator is available for several indexes. Try them out and see which ones give you a good “under the hood” look at the broader market.

StockChart Tip. Click the charts of SPY and QQQ in the article to see a live chart.

Then, save the charts to one of your ChartLists. Not sure how to create ChartLists? Check out this tutorial.

Disclaimer: This blog is for educational purposes only and should not be construed as financial advice. The ideas and strategies should never be used without first assessing your own personal and financial situation, or without consulting a financial professional.

Top 10 Copper Producers by Country

In 2024, concern grew about copper supply as copper mines in the top copper-producing countries continued to age without new mines to replace them.

Additionally, copper demand from electrification is expected to rise significantly in the coming years.

The competing forces of the global macroeconomic situation and a tightening supply and demand situation caused major swings in the copper price last year, and the red metal set a new all-time high in May 2024 as it moved above the US$5 per pound mark for the first time.

Despite a tight supply situation, demand from the energy transition has largely been muted as China, traditionally the largest consumer of copper for its infrastructure, works to stimulate its flagging economy.

The forecast for copper over the next few years is that the copper market will move into supply deficits, which in turn should provide more tailwinds for the price of copper and greater upside to company balance sheets.

For investors interested in copper, it’s worth looking at production by country. According to the latest US Geological Survey data, global copper production reached 23 million metric tons (MT) in 2024. Mining output figures for this article were supplemented with data provided by Mining Data Online (MDO).

Chile again took the crown to become the top copper producing country last year, but some of the others on the list may surprise you. Read on to find out the top 10 copper countries and what mines are driving each country’s copper output.

1. Chile

Copper production: 5.3 million metric tons

In 2024, Chile produced 5.3 million metric tons of copper, making it the world’s largest copper producing country with about 23 percent of the total global copper output.

Naturally, many of the world’s leading copper miners have substantial operations in Chile, including the state-owned Codelco, Anglo American (LSE:AAL,OTCQX:AAUKF), Glencore (LSE:GLEN,OTC Pink:GLCNF) and Antofagasta (LSE:ANTO,OTC Pink:ANFGF).

Chile is also home to BHP’s (ASX:BHP,NYSE:BHP,LSE:BHP) Escondida, the largest copper mine in the world. According to BHP’s 2024 annual report, the mine produced 1.13 million metric tons of copper in 2024.

However, Chile’s copper production is expected to rebound to record levels in 2025, according to S&P Global, to hit a projected 6 million MT as new mines ramp up their output.

2. Democratic Republic of Congo

Copper production: 3.3 million metric tons

In 2024, the Democratic Republic of Congo (DRC) produced 3.3 million metric tons of copper, accounting for more than 11 percent of global copper output. The DRC has increased its copper production rapidly in recent years, and its 2024 output marked a significant rise from the 2.93 million metric tons of copper produced the previous year.

One contributor to this increase is Phase 3 of the Ivanhoe Mines (TSX:IVN,OTCQX:IVPAF) Kamoa-Kakula project, which achieved commercial production in August 2024. A joint venture with partner Zijin Mining Group (OTC Pink:ZIJMY,SHA:601899), Kamoa-Kakula produced 437,061 MT of copper in 2024, an increase from the 393,551 MT produced in 2023. Ivanhoe is expecting further increases in production in 2025 and set its guidance for the year at 520,000 and 580,000 MT of copper.

3. Peru

Copper production: 2.6 million metric tons

In 2024, Peru produced 2.6 million metric tons of copper, according to USGS data. The total is down 160,000 MT from its copper output in 2023.

Among the factors impacting the declines was a 3.7 percent drop at Freeport McMoRan’s (NYSE:FCX) Cerro Verde, the largest copper mine in Peru. According to data from MDO, Cerro Verde produced 1.94 million metric tons of copper concentrate in 2023. Freeport McMoRan indicated in its Q1 2024 report that declines in its South American operations were due to lower volumes of stockpiled leach ore and lower milling rates associated with maintenance.

Other significant copper operations in Peru include Anglo American’s Quellaveco mine and Southern Copper’s (NYSE:SCCO) Tia Maria mine. The majority of copper produced in Peru is shipped to China and Japan, and South Korea and Germany are other top export destinations.

4. China

Copper production: 1.8 million metric tons

In 2024, China produced 1.8 million metric tons of copper. The total was marginally lower than the 1.82 million metric tons produced in 2023, but also marks a steady decline over the past few years, seeing production slip from a recent high of 1.91 million metric tons in 2021.

However, when it comes to refined copper production, China is by far the winner. In 2024, its refined copper production totaled 12 million metric tons, representing more than 44 percent of global refined copper production and six times the production of Chile, the next-top refinery producer. China also holds the world’s highest copper reserves at 190 million MT.

Zijin Mining Group, a leading metal producer in China, owns the Qulong copper-molybdenum-silver-gold mine in Tibet. The company purchased a 50.1 interest in the owner of the Qulong mine in 2024 and is working to consolidate 100 percent ownership. Zijin increased its mine production in 2024 and it is now the largest copper mine in China.

According to MDO, the Qulong mine produced 340 million pounds of copper in 2023. While its 2024 copper production is still being finalized, it is estimated to have increased to 366 million pounds.

5. Indonesia

Copper production: 1.1 million metric tons

In 2024, Indonesia produced 1.1 million metric tons of copper, passing the United States and Russia to become the fifth highest copper producer. The country’s copper production has increased steadily in recent years, and is up significantly from 907,000 MT in 2023 and 731,000 MT in 2021.

Freeport McMoRan’s Grasberg complex is the country’s largest copper mine. According to MDO data, the mine produced 1.66 billion pounds of copper in 2023.

Another of the country’s largest operations is PT Amman Mineral’s (IDX:AMMN,FWB:U4Z) Batu Hijau mine. While production in 2023 was modest compared to Grasberg at 542 million pounds of copper concentrate, it’s estimated that 2024 will see production increase significantly to 1.84 billion pounds as the mine begins processing high-grade ore from its Phase 7 cutback.

In mid-2024, Amman Minerals commissioned a smelting facility that will process 900,000 metric tons of copper concentrate annually to produce 222,000 MT of copper cathodes and 830,000 MT of sulfuric acid.

6. United States

Copper production: 1.1 million metric tons

The United States produced 1.1 million metric tons of copper in 2024. While only 30,000 metric tons less than its 2023 production totals, the country’s 2024 output was a sharp decline from the 1.23 million MT it produced in 2022.

The majority of US copper comes from Arizona, which accounts for 70 percent of domestic supply. Other states with significant copper output include Michigan, Missouri, Montana, Nevada and New Mexico. Overall, 17 mines are responsible for 99 percent of copper production in the United States.

Freeport McMoRan’s Morenci mine in Arizona, a joint venture with Sumitomo (TSE:8053), is the largest copper mine in the US. According to MDO data, the mine produced 700 million pounds of copper metal in 2024 and has 12.63 million pounds of proven and probable reserves.

Other significant operations include Freeport McMoRan’s Safford and Sierrita mines, at which copper production totaled 249 million MT and 165 million MT respectively.

7. Russia

Copper production: 930,000 metric tons

Russia produced 930,000 metric tons of copper in 2024, a sizable increase from the 890,000 MT produced the previous year.

One of the key contributions to the rise in Russian copper output is the ramp-up in Phase 1 production at Udokan Copper’s Udokan mine in Siberia. Although the mine experienced multiple fires at the very end of 2023, copper production was reported to be unaffected. The mine was expected to produce up to 135,000 metric tons of copper in 2024. This is expected to grow to 450,000 MT once Phase 2 comes online in 2028.

8. Australia

Copper production: 800,000 metric tons

In 2024, Australia produced 800,000 metric tons of copper, a slight increase from the 778,000 MT produced in 2023.

The country’s largest copper operation is BHP’s Olympic Dam mine in South Australia. According to MDO data, 2024 marked a 10 year high in total copper production for Olympic Dam at 216,000 metric tons.

The state of Queensland is home to the Mount Isa complex, run by a subsidiary of Glencore. While it is one of Australia’s largest copper producers, the operations will be closed in the second half of 2025.

Australia may have modest output compared to those at the top of the list, but it is tied with Peru for the second highest copper reserves in the world at 100 million metric tons, behind only China with 190 million metric tons.

9. Kazakhstan

Copper production: 740,000 metric tons

In 2024, Kazakhstan produced 740,000 metric tons of copper, on par with 2023’s production totals. Although its production was unchanged year-over-year, the country entered the top 10 copper producers list this year, leapfrogging over Mexico and Zambia.

Kazakhstan’s copper output is up substantially compared to just a few years ago, with the country producing just 510,000 MT in 2021.

The nation plans to continue that trend, releasing a National Development Plan in February 2024 that aims to increase mineral production by 40 percent by 2029. The plan will involve increased exploration, project co-financing and tax incentives for investment.

Among the country’s largest mining companies is private firm KAZ Minerals, which owns the Aktogay mine. According to the company’s Q4 2024 production report, the mine produced 228,800 metric tons of copper during the year, a decline from the 252,400 MT produced in 2023.

10. Mexico

Copper production: 700,000 metric tons

Rounding out our list of top copper producers, Mexico produced 700,000 metric tons of copper in 2024, just 1,000 MT above its 2023 output.

The Buenavista del Cobre mine in Sonora, owned by Grupo Mexico (BMV:GMEXICOB), is the largest copper mine in the country. According to MDO data, the mine produced 725 million pounds of copper concentrate and 193 million pounds of copper cathode in 2023.

In addition, Grupo Mexico also owns Mexico’s second-largest copper mine, La Caridad, which produced 387,000 MT of copper concentrate and 51 million pounds of copper cathode in 2023.

Securities Disclosure: I, Dean Belder, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies are working hard to make advancements that can help patients.

Stem cells serve as an internal repair system in the body. They can divide without limit to replenish other cells as long as the body is still alive. Unsurprisingly, there’s a lot of promise for medical advancements, and there are already stem cell treatments approved by the US Food and Drug Administration (FDA). Still, there is a lot of room for further advancements, and plenty of lab work still needs to be done before stem cell products can be used as cell-based therapies or regenerative medicines.

A report from Grand View Research projects that the global stem cell market will reach US$28.89 billion by 2030. The research firm sees “the rising number of stem cell banks, growing focus on increasing therapeutic potential of these, and extensive research for the development of regenerative medicines” as drivers of this market. The stem cell market and the value of regenerative medicine stocks is expected to grow further via increased government funding for cancer research and the development of cellular therapies to treat various cancers.

Grand View Research reports that in 2024 the pharmaceutical and biotechnology companies segment captured the largest revenue share for the stem cell therapy market at 54.19 percent.

1. AstraZeneca (NASDAQ:AZN)

Company Profile

Market cap: US$228.3 billion

First on this list of the top NASDAQ stem cell company stocks is multinational pharma and biotech firm AstraZeneca, which also specializes in other therapeutic areas, including oncology, cardiovascular diseases, the respiratory and central nervous systems and pain control.

While it may be the largest company on this list by market cap, the pharma giant has been slower than its peers in staking a position in the cell therapy market. Its particular focus in oncology is the treatment of solid tumors. The company is also looking at stem cell therapies to treat life-threatening chronic kidney disease and liver disease.

AstraZeneca acquired biotech firm Neogene Therapeutics in 2023, bringing the company’s expertise on T-cell receptor therapies into AstraZeneca’s fold.

Its long-term strategy in this area is to develop ‘off-the-shelf’ allogenic CAR-T therapies to increase the availability and accessibility of the treatments.

2. Amgen (NASDAQ:AMGN)

Company Profile

Market cap: US$160.05 billion

A global leader in biotech, Amgen is heavily invested in gene-based research and uses advanced human genetics to develop and manufacture therapeutics targeting a variety of diseases with unmet medical needs.

The biotech firm has a multi-year fund agreement with Canada’s Center for Commercialization of Regenerative Medicine (CCRM), which specializes in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. Under the multi-year agreement, both CCRM and Amgen will fund early stage regenerative medicine-based technologies and therapies with research conducted in institutions that are part of CCRM’s global network.

In May 2024, the US FDA approved Amgen’s Imdelltra for the treatment of adult patients with extensive-stage small cell lung cancer, making the drug the first and only T-cell engager therapy available for treating this condition. The therapy activates the patient’s own T cells to attack particular tumor cells.

3. Gilead Sciences (NASDAQ:GILD)

Company Profile

Market cap: US$137.13 billion

Global biopharmaceutical company Gilead Sciences specializes in developing breakthrough medicines to prevent and treat serious diseases such as HIV, viral hepatitis and cancer.

One of the stem cell therapies in its product portfolio is Yescarta, a CAR-T cell therapy for blood cancer and the first such therapy for certain types of non-Hodgkin’s lymphoma. Yescarta aids a patient’s immune system in fighting the disease. Gilead currently has at least eight cell therapy candidates in its product pipeline, including three in Phase 3 clinical studies targeting high-risk lymphomas and myeloma.

4. Sanofi (NASDAQ:SNY)

Company Profile

Market cap: US$134.81 billion

French multinational pharmaceutical company Sanofi develops therapeutic products for diabetes and cardiovascular diseases, oncology, immunology, multiple sclerosis, rare diseases, rare blood disorders and vaccines. Its product portfolio includes Mozobil, a hematopoietic stem cell mobilizer that helps bone marrow release stem cells into the bloodstream for transplant into the body.

In 2021, the firm bolstered its regenerative medicine business through the US$1.9 billion acquisition of Kadmon, adding FDA-approved stem cell transplant product Rezurock to its portfolio. Sanofi has since partnered with privately held biotech company Scribe Therapeutics to develop CRISPR-based cell therapies targeting cancers.

The company also has a licensing agreement with Innate Pharma (NASDAQ:IPHA) as the two companies collaborate on developing natural killer cell therapeutics in oncology. One investigational drug candidate under this collaboration is SAR’579, which is in Phase 1/2 studies for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia, B cell acute lymphoblastic leukemia and high-risk myelodysplasia. SAR’579 received FDA Fast Track Designation for the treatment of acute myeloid leukemia.

5. Vertex Pharmaceuticals (NASDAQ:VRTX)

Company Profile

Market cap: US$123.34 billion

Vertex Pharmaceuticals has developed a number of approved treatments for cystic fibrosis, and has a pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes.

Vertex and its partner CRISPR Therapeutics (NASDAQ:CRSP) co-developed drug Casgevy, a CRISPR/Cas9 genome-edited cell therapy, received FDA approval in December 2023 for the treatment of sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises. Casgevy is the first ever treatment based on CRISPR technology to be approved for the US market. In 2024, the drug received validation from the European Medicines Agency and Health Canada for this indication as well.

In addition, Vertex has two active clinical trials for type 1 diabetes cell therapy: X-880, an investigational allogeneic stem cell-derived, insulin-producing islet cell therapy in Phase 1/2/3 clinical trials; and VX-264, designed to be a surgically implanted device in phase 1/2 clinical trials.

6. BioNTech (NASDAQ:BNTX)

Company Profile

Market cap: US$28.67 billion

Immunotherapy company BioNTech is advancing novel therapies for diseases such as cancer. The company combines computational discovery and therapeutic drug platforms to rapidly develop new biopharmaceutical products. The company is best known today for its mRNA vaccine development and in-house manufacturing capabilities, as well as its COVID-19 vaccine, created with partner Pfizer (NYSE:PFE).

BioNTech is engaged in collaborative partnerships aimed at assembling mRNA vaccine candidates for a range of infectious diseases. BioNTech’s portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, CAR-T cell therapies, bispecific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

The most advanced of its CAR-T product candidates is BNT211, which comprises two drug products designed to induce an immune response against various CLDN6-positive solid tumors, such as ovarian cancer, sarcoma, testicular cancer, endometrial cancer and gastric cancer. BNT211 is in a Phase 1 trial in patients with CLDN6-positive relapsed or refractory advanced solid tumors.

7. BeiGene (NASDAQ:ONC)

Company Profile

Market cap: US$26.72 billion

Biotechnology company BeiGene specializes in the development of drugs for cancer treatment across a broad range of areas, including esophageal squamous cell carcinoma, non-small cell lung cancer, mantle cell lymphoma, non-Hodgkin’s lymphoma and ovarian cancer. Its clinical development pipeline includes 12 advanced Phase 3 programs.

BeiGene has a strategic partnership with Shoreline Biosciences for the development and commercialization of a genetically engineered natural killer cell therapy.

BeiGene’s bruton tyrosine kinase inhibitor Brukinsa gained FDA approval in early 2023 for patients with chronic lymphocytic leukemia or small lymphocytic leukemia, both forms of non-Hodgkin’s lymphoma.

The company’s monoclonal antibody Tevimbra garnered FDA approval in early 2024 for the treatment of advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy. Near the end of the year, the European Commission gave the green light to the drug for first-line treatment of advanced/metastatic esophageal squamous cell carcinoma and gastric or gastroesophageal junction cancer, while the FDA approved it for first-line treatment of gastric and gastroesophageal junction cancers in combination with chemotherapy.

8. BioMarin Pharmaceutical (NASDAQ:BMRN)

Company Profile

Market cap: US$13.1 billion

BioMarin Pharmaceutical develops and commercializes therapies for patients with serious, life-threatening genetic diseases and medical conditions.

The global biotech company focuses on diseases with critical unmet medical needs, as well as products with an opportunity to be first to market or to offer significant benefits over existing products. BioMarin’s portfolio includes eight commercial products and multiple clinical and preclinical product candidates across its therapeutic areas.

9. Moderna (NASDAQ:MRNA)

Company Profile

Market cap: US$12.98 billion

Biotechnology and pharmaceutical company Moderna is a pioneer in the field of mRNA. The company’s assets include a diverse clinical portfolio of vaccines and therapeutics, plus a large intellectual property portfolio in areas such as mRNA and lipid nanoparticle formulation; it also has an integrated manufacturing plant that allows for both clinical and commercial production.

These assets, along with Moderna’s network of domestic and overseas government and commercial collaborators, allowed for the rapid development of one of the world’s most effective COVID-19 vaccines.

The other therapeutics and vaccines in the company’s pipeline are targeting infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has 23 development programs underway across these areas.

10. Bio-Techne (NASDAQ:TECH)

Company Profile

Market cap: US$10.3 billion

Bio-Techne develops, manufactures and sells reagents, diagnostic instruments and bioprocessing services for research and clinical applications, including drug discovery. The company’s revenue segments include diagnostics and spatial biology, and protein sciences.

Bio-Techne offers tailored technologies and services for its life science customers developing and producing immune cell, regenerative and gene therapies. The company expanded its Advanced Cell Diagnostics branded RNAscope probe portfolio in February 2025.

‘With over 12,000 citations in clinical and translational research combined, our expanded portfolio of gold-standard RNAscope probes enables customers to accelerate biomarker validation and ultimately improve lives,’ said Dr. Matt McManus, president of Bio-Techne’s diagnostics and spatial biology segment.

FAQs for stem cell stocks

What are stem cells?

Stem cells are the building blocks of life, with special capabilities that are particularly important in both the early and later stages of a human’s lifecycle. Human stem cells have the ability to develop into a variety of different cell types in the body, including organ-specific cells, as well as muscle tissue and bone marrow cells; they can even renew themselves.

What is stem cell therapy?

Stem cell therapy is the use of stem cells to treat or prevent a disease or condition, including some cancers such as leukemia, lymphoma, multiple myeloma and neuroblastoma. Cell therapy involves the direct administration of cells into the body to promote the body’s natural ability to heal itself.

What is stem cell banking?

Stem cell banking is the process of collecting, processing and cryogenically storing potentially life-saving stem cells for future use in therapies and regenerative medicine.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Could Bitcoin Reach $200000? Market & Expert Insights

Bitcoin attracts bold predictions. Recent forecasts show that this top cryptocurrency may soon hit Bitcoin Reach $200000. Many trusted sources, including Yahoo Finance, CoinDesk, Bloomberg, and CNBC, have reported this forecast. This public news reflects rising optimism among market experts amid changing economic conditions.

Market Sentiment and Economic Drivers

Many analysts believe that economic uncertainty and rising prices create a strong chance for Bitcoin to serve as a safe asset. Investors now see Bitcoin as a reliable store of value. They shift funds to cryptocurrencies when they lose trust in traditional assets. In addition, new regulations in key markets push both large and small investors to spread their money across various assets.

Technical Analysis and Price Trends

Technical data supports a potential price surge. Long-term charts show an upward trend, while short-term drops offer good buying points. Trading volumes and network activity grow each day. Experts point to a limited supply and high demand as key reasons that Bitcoin Reach $200000 upto.

Investor Implications and Risk Management

Investors must stay alert in this volatile market. They should manage risk by diversifying their portfolios. Many experts advise reviewing holdings and allocating funds wisely. They also recommend keeping up with the latest market news and technical signals to guide decisions.

Conclusion

This forecast that Bitcoin may reach $200,000 comes from strong market sentiment, positive technical trends, and a unique economic climate. However, investors face a volatile market that demands caution. Experts urge both individual and institutional investors to monitor these trends closely and prepare for various market moves.

While reaching $200,000 is not guaranteed, this forecast offers valuable insight into the ever-changing crypto market. It shows that the market can shift quickly and that informed decisions are key. Investors should act wisely and stay updated on news and trends. By doing so, they can protect their investments and uncover new opportunities in the fast-paced world of cryptocurrencies.

The post Could Bitcoin Reach $200000? Market & Expert Insights appeared first on FinanceBrokerage.